Baxter (NYSE:BAX), a leading global medical products company and a global innovator in renal care, today signed an agreement with the Olayan Group, a private multinational enterprise, on increasing its investment in Baxter Company Limited (BCL), a joint venture and manufacturing plant of both companies in the southern region of Saudi Arabia. Baxter and Olayan established their partnership 10 years ago to build a state of the art manufacturing facility to produce medical solutions for peritoneal dialysis and IV solutions that currently serves more than 1500 renal dialysis patients in the Saudi region. In the future, the factory will expand its supply beyond Saudi Arabia to the entire Middle East as part of a global supply chain ecosystem.

The agreement underscores the partner’s commitment to Saudi and the region to further improve clinical outcomes for a wide range of patients suffering from chronic kidney failure (CKD). In addition to expanding capacity in the current manufacturing facility.

“For more than 60 years, Baxter has partnered with the nephrology community to focus on pioneering care in both hemodialysis and peritoneal dialysis”, said Mazen Dalati, General Manager of Baxter Middle East Africa. He continued:” The agreement with Olayan is an important milestone on our way to bring that pioneering spirit to Saudi through new therapies and remote patient management.”

Baxter is bringing into this venture Claria with SHARESOURCE, a new technology that allows remote monitoring of peritoneal therapy patients while in their home.

SHARESOURCE extends healthcare providers’ reach by allowing visibility to their home patients’ adherence patterns, which may allow for earlier intervention. The telehealth platform was introduced to the Saudi market in 2016. It is the only globally available two-way technology that enables healthcare professionals to remotely monitor and manage therapy from their clinic. Furthermore, Sharesource includes the ability to change a patient’s prescription setting remotely.

Baxter and Olayan consider themselves partners of the Ministry of Health in their joint effort to facilitate Saudi Arabia’s Vision 2030 by providing lifesaving therapies to patients. Additionally, Baxter and Olayan are committed to localizing the latest technology and know-how for the benefit of the Saudi market.

-Ends-

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com

About Olayan Group

The Olayan Group, a private multinational enterprise, is an international investor and a diverse commercial and industrial concern with operations in the Middle East. With offices in Saudi Arabia, Europe, and the US, the Group’s global investment team focuses on public and private equities, real estate, fixed income securities, and other specialized assets. The commercial side of the Group comprises more than 40 companies and is centered in Saudi Arabia, where the Group originated in 1947. They are engaged in distribution, manufacturing, and services. Many of these companies operate in partnership with leading multinational or regional firms. Some have operations in other Gulf countries and the wider Middle East.

© Press Release 2018

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.